Basilea Pharmaceutica AG (BPMUF) - Grey Market
  • Mon, Feb. 29, 8:59 AM
    • Basilea Pharmaceutica AG (OTC:BPMUF): FY15 EPS of -CHF6.09
    • Contract Revenue of CHF51.2M (+21.6% Y/Y)
    • Press Release
    | Mon, Feb. 29, 8:59 AM
  • Jun. 12, 2012, 8:19 AM

    (GSK) is making another bolt-on acquisition to strengthen its lineup, agreeing to pay an initial £146M ($227M) to acquire eczema drug Toctino from Swiss biotech Basilea (BPMUF.PK). GSK will pay another £50M if Toctino passes its Phase III trial and receives FDA approval, and royalties on U.S. sales starting three years after launch.

    | Jun. 12, 2012, 8:19 AM
Company Description
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland. The company focuses on providing innovative pharmaceutical products in the therapeutic areas of bacterial infections, fungal infections and oncology, targeting the medical challenge of rising resistance and non-response to... More
Sector: Healthcare
Industry: Drug Related Products
Country: Switzerland